Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

2020348 citationsJournal Articlebronze Open Access

Authors

Karim Fizazi · Université Paris-Saclay

Neal D. Shore · Carolina Urologic Research Center

Teuvo L.J. Tammela · Tampere University

Albertas Ulys · National Cancer Institute

Egils Vjaters · Pauls Stradiņš Clinical University Hospital

S. Polyakov · N.N. Alexandrov National Cancer Centre

Mindaugas Jievaltas

Abstract

Among men with nonmetastatic, castration-resistant prostate cancer, the percentage of patients who were alive at 3 years was significantly higher among those who received darolutamide than among those who received placebo. The incidence of adverse events was similar in the two groups. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614.).

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 11, pp. 1040-1049

DOI: 10.1056/nejmoa2001342

Field-Weighted Citation Impact: 29.24